Merck announced a weight loss drug deal Wednesday with China-based Hansoh worth up to $2 billion for the pill code-named HS-10535. It includes an upfront $112 million licensing rights payment for global sales outside China. Hansoh could get an additional $1.9 billion if it reaches clinical, regulatory and commercial milestones. The drug is experimental and works by targeting a gut hormone called GLP-1 like Wegovy does. "Through this agreement, we ...